Results 71 to 80 of about 2,285,924 (374)
Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study
American Journal of Hematology, EarlyView.ABSTRACT Pure red cell aplasia (PRCA) is the most frequent autoimmune cytopenia associated with thymic tumors (TTs). In a nationwide retrospective study, we included 41 patients (22 women, median age 62 years). At PRCA diagnosis, the mean hemoglobin level was 6.6 ± 2.1 g/dL, and the reticulocyte count was 6 ± 5 × 109/L. PRCA was diagnosed before TT (8%,
Mylène Hemmer +9 more
wiley +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2015 Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective ...
Emmanouil Petrou +6 more
doaj +1 more source
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]
, 2016 The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus +5 more
core +2 more sources
American Journal of Hematology, EarlyView.ABSTRACT In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (allo‐HSCT), and the activity of CPX‐351 in specific s‐AML subgroups are unclear.
Fabio Guolo +56 more
wiley +1 more source
Haematologica, 2017 Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β ...
Thomas Cluzeau +11 more
doaj +1 more source
Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes [PDF]
, 2012 In vivo, half-lives of cytidine analogues such as 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), are determined largely by cytidine deaminase (CDA), an enzyme that rapidly metabolizes these drugs into inactive uridine ...
Ania Jankowska +13 more
core +1 more source
Haematologica, 2019 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA).
N. Maslah +16 more
semanticscholar +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Pre‐engraftment syndrome (PES) is a unique complication of cord blood transplantation (CBT) whose risk factors and impact on transplant outcomes remain controversial. Using a nationwide database in Japan, we analyzed a total of 3734 patients who underwent single‐unit CBT.
Masatoshi Sakurai +27 more
wiley +1 more source
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Haematologica, 2014 Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide range of clinical manifestations and eventual outcomes. Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease and which ...
Rafael Bejar
doaj +1 more source
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish Registry [PDF]
, 2015 The benefit of azacitidine treatment in survival of high risk myelodysplastic syndromes (MDS) patients compared to conventional care treatment (CCT) has not been established outside clinical trials.
Amigo, M. L. +9 more
core +1 more source